About Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from About multiple sclerosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In About Multiple Sclerosis Today - Breaking & Trending Today

Janssen: New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM? (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients ....

Janssen Cilag Gm , Alexandra Nisipeanu , Jennifer Mcintyre , Prinzj Ponesimod , Janssen Cilag International , None Of The Janssen Pharmaceutical Companies , European Commission , National Multiple Sclerosis Society , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Actelion Pharmaceuticals Ltd , Exchange Commission , Janssen Global Services , Companies Of Johnson , Idorsia Pharmaceuticals Ltd , European Committee , Treatment Research , Multiple Sclerosis , About Multiple Sclerosis , Pharmaceutical Companies , Cardiovascular Metabolism , Infectious Diseases Vaccines , Janssen Cilag , Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Janssen Pharmaceutica ,

Janssen: European Commission approves PONVORYTM ? (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

(0)
The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1
The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS
Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod s efficacy and safety
1,2,3
Approval builds on Janssen s deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS
Janssen, the Pharmaceutical Companies of Johnson Johnson, announced today that the European Commission (EC) has approved PONVORY ?
(ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features. ....

United States , Alexandra Nisipeanu , Gavin Giovannoni , Jennifer Mcintyre , Prinzj Ponesimod , Chris Delorefice , None Of The Janssen Pharmaceutical Companies , European Commission , Americas Committee For Treatment , Sclerosis Association Of America , National Multiple Sclerosis Society , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Actelion Pharmaceuticals Ltd , Exchange Commission , Companies Of Johnson , European Medicines Agency , Idorsia Pharmaceuticals Ltd , Research In Multiple Sclerosis , Pharmaceutical Companies , Professor Gavin Giovannoni , Queen Mary University , About Multiple Sclerosis , Cardiovascular Metabolism , Infectious Diseases Vaccines ,